Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02965170 · ClinicalTrials.gov registry record
Validation of a Laboratory Test Measuring Natalizumab (Tysabri®) Serum Levels in MS
A clinical trial, sponsored by Rocky Mountain MS Research Group.
- Completed
- Registry status
- 109
- Enrollment target
NCT02965170: Completed study, sponsored by Rocky Mountain MS Research Group.
NCT02965170 is a clinical trial that has completed, run by Rocky Mountain MS Research Group. The registered enrollment target is 109 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02965170 has completed, sponsored by Rocky Mountain MS Research Group.
- COMPLETED
- Registry status
- 109 participants
- Enrollment target
Study Summary
Validating a peptide-based laboratory test enabling the measurement of Tysabri® serum levels (pharmacokinetics, PK) in multiple sclerosis patients undergoing therapy. The results of this newly developed test will be compared to Tysabri® serum levels measured in parallel using an independent test. We will also simultaneously measure a pharmacodynamic marker of Tysabri®, receptor saturation levels on blood immune cells, which is thought to correlate with Tysabri® serum levels.
Primary Outcome
Validate a novel peptide-based laboratory test enabling the measurement of nadir natalizumab (Tysabri®) serum levels in multiple sclerosis patients undergoing therapy compared to the traditional ELISA assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2016-10 |
| Est. Completion | 2018-05 |
What the finished NCT02965170 record still lists
NCT02965170 is an observational study that tracks outcomes without assigning an intervention. The registered 109 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02965170 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02965170 about?
NCT02965170 is a clinical study titled "Validation of a Laboratory Test Measuring Natalizumab (Tysabri®) Serum Levels in MS". Validating a peptide-based laboratory test enabling the measurement of Tysabri® serum levels (pharmacokinetics, PK) in multiple sclerosis patients undergoing therapy. The results of this newly developed test will be compared to Tysabri® serum levels measured in parallel using an independent test. We...
What is the current status of trial NCT02965170?
This trial is currently completed. The enrollment target is 109 participants. The study started on 2016-10. Estimated completion is 2018-05.
Who is sponsoring clinical trial NCT02965170?
This trial is sponsored by Rocky Mountain MS Research Group, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02421380 · 109 participants · NA
Characterization of Hyperpolarized Pyruvate MRI Reproducibility
- NCT04526600 · 109 participants · NA
Fidgeting and Attentional and Emotional Regulation in ADHD
- NCT04835584 · 109 participants · Phase 1
KRT-232 and TKI Study in Chronic Myeloid Leukemia
- NCT06626516 · 109 participants · Phase 1
Tebentafusp-tebn With LDT in Metastatic UM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia